Target / Biomarker
Discovery & Validation
Euretos is an AI (Artificial Intelligence) platform used by pre-clinical researchers for in-silico discovery & validation of targets and biomarkers. World leading pharma, biotech and academic institutions use it to accelerate their research. Available as subscription, consulting service or direct access
EURETOS AI PLATFORM
In Silico Multi Omics
Drive your in vitro and in vivo research by in silico multi omics analysis. Ask Euretos and evaluate how molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology.
FIND OUT MORE
Euretos presenting in the Scale-Up track at the Innovation for Health conferenceMonday 03 February 2020
Arie Baak, co-founder of Euretos, will be presenting at the Innovation for Health conference. This year’s event will take place in Rotterdam and Euretos will present as part of the Scale-Up track, February 13th at 11:30 in the Hudag Room. In ...
Euretos is featured in an overview of 26 Dutch start-ups and scale-ups that help enable the transition to animal-free innovationWednesday 04 December 2019
The Transition Programme for Innovation without the use of animals (TPI) is aimed at increasing the pace of animal-free innovation through temporary, flexible networks and projects. The TPI is a broad partnership of several Dutch government ministr ...
Prof David Webb (The Scripps Research Institute)
“The Euretos AI Platform is nothing less than an in silico way to save all drug and biotech researchers an infinite amount of blood, sweat and tears by providing
them with a powerful knowledge discovery platform.
The Euretos AI Platform allows the researcher to rapidly assess whether a given target, research area, etc., is related, even distantly, to another such entity thus allowing one to uncover hidden connections, leading to new knowledge.In the drug discovery arena, this thing is a gold mine.